Hospital
Mercy Hospital Jefferson
Mercy Hospital Jefferson was paid $27.83M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoMERCY HOSPITAL JEFFERSON
FESTUS, MO 63028
FESTUS, MO 63028
33aNPI1508859661assigned 08/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.83M
24GClaims264,740
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#13 of 74
Median peer was paid$4.44M
This provider vs. median6.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,287 | $6.12M | |
| 2019 | 39,293 | $5.62M | |
| 2020 | 32,269 | $3.29M | |
| 2021 | 34,358 | $1.71M | |
| 2022 | 38,239 | $3.04M | |
| 2023 | 47,048 | $4.34M | |
| 2024incomplete | 41,246 | $3.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 34,917 | 27,016 | $5.94M |
| Y7506 | 17% | 33,842 | 28,948 | $4.63M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 24,099 | 18,942 | $3.56M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 24,404 | 18,487 | $2.92M |
| X4011 | State-specific procedure code | 10% | 12,018 | 11,344 | $2.86M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.5% | 36,818 | 33,263 | $1.80M |
| 80053 | Comprehensive metabolic panel | 5.4% | 32,522 | 30,080 | $1.51M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 5,228 | 5,026 | $512K |
| 81001 | 1.6% | 7,443 | 7,105 | $444K | |
| 59025 | Fetal non-stress test | 1.3% | 3,470 | 2,248 | $364K |
| X4006 | <1% | 377 | 334 | $248K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,862 | 2,692 | $240K |
108 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,478 | $235K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,091 | $227K |
| X4003 | <1% | 1,686 | $202K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,752 | $157K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,330 | $153K |
| 97597 | <1% | 1,990 | $146K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 738 | $129K |
| 84484 | <1% | 3,583 | $112K | |
| 83690 | <1% | 1,336 | $108K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 317 | $104K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 410 | $85K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 378 | $84K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,662 | $83K |
| 85610 | <1% | 1,090 | $81K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,864 | $71K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 382 | $60K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 557 | $51K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 727 | $49K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 123 | $43K |
| 85730 | <1% | 303 | $39K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 440 | $37K |
| 87081 | <1% | 503 | $35K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 215 | $33K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 124 | $29K |
| 83880 | <1% | 688 | $29K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 94 | $26K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 942 | $22K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 263 | $20K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 245 | $20K |
| 81003 | <1% | 587 | $17K | |
| 86140 | <1% | 282 | $16K | |
| 85652 | <1% | 237 | $15K | |
| 87631 | <1% | 46 | $14K | |
| 36591 | <1% | 227 | $14K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 147 | $14K |
| 82077 | <1% | 995 | $14K | |
| 84703 | <1% | 228 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 148 | $12K |
| 81025 | <1% | 113 | $12K | |
| 80076 | <1% | 174 | $10K | |
| 87807 | <1% | 26 | $10K | |
| 82565 | <1% | 147 | $10K | |
| 85027 | <1% | 41 | $9K | |
| 86235 | <1% | 62 | $9K | |
| 93017 | <1% | 61 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 26 | $8K |
| 83516 | <1% | 77 | $8K | |
| 0240U | <1% | 66 | $8K | |
| 82728 | <1% | 302 | $8K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 77 | $6K |
| 83615 | <1% | 329 | $6K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13 | $6K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 47 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $5K |
| 84466 | <1% | 195 | $5K | |
| 86200 | <1% | 38 | $4K | |
| 86225 | <1% | 40 | $4K | |
| 87634 | <1% | 12 | $4K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 39 | $4K |
| 83540 | <1% | 195 | $4K | |
| 86431 | <1% | 37 | $4K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 31 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 698 | $4K |
| 96367 | <1% | 95 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 105 | $3K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 16 | $3K |
| 82746 | <1% | 121 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 185 | $3K |
| Y7507 | <1% | 52 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 25 | $2K |
| 82607 | <1% | 94 | $2K | |
| 95816 | <1% | 12 | $2K | |
| 83735 | <1% | 608 | $2K | |
| 82550 | <1% | 12 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 26 | $976.25 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $948.26 |
| 87653 | <1% | 13 | $858.88 | |
| 86160 | <1% | 12 | $843.47 | |
| 74018 | <1% | 12 | $737.02 | |
| 80061 | Lipid panel | <1% | 55 | $694.62 |
| 86039 | <1% | 12 | $667.47 | |
| 73120 | <1% | 12 | $639.68 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $637.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 120 | $556.10 |
| 86038 | <1% | 12 | $495.93 | |
| 77336 | <1% | 21 | $403.42 | |
| 84702 | <1% | 41 | $363.07 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $337.96 |
| J3490 | Unclassified drugs | <1% | 1,798 | $335.70 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 46 | $189.73 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27 | $168.42 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27 | $168.42 |
| 83605 | <1% | 27 | $167.46 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $140.35 |
| 84165 | <1% | 13 | $63.27 | |
| 87088 | <1% | 13 | $29.12 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 85 | $28.35 |
| J2704 | Injection, propofol, 10 mg | <1% | 292 | $9.72 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 100 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 76 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 180 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 39 | $0.00 |
| A9270 | Non-covered item or service | 0% | 68 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 59 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 16 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 15 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 46 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialECKENFELS, DAN (PRESIDENT)